JP2021506769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506769A5 JP2021506769A5 JP2020531748A JP2020531748A JP2021506769A5 JP 2021506769 A5 JP2021506769 A5 JP 2021506769A5 JP 2020531748 A JP2020531748 A JP 2020531748A JP 2020531748 A JP2020531748 A JP 2020531748A JP 2021506769 A5 JP2021506769 A5 JP 2021506769A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- gram
- lytic
- fragment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 230000002101 lytic effect Effects 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 241000894006 Bacteria Species 0.000 claims 17
- 239000006166 lysate Substances 0.000 claims 15
- 241000894007 species Species 0.000 claims 12
- 230000001420 bacteriolytic effect Effects 0.000 claims 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 8
- 230000001320 lysogenic effect Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 2
- 241000589516 Pseudomonas Species 0.000 claims 2
- 229960004682 cefoperazone Drugs 0.000 claims 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 241000588923 Citrobacter Species 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000589602 Francisella tularensis Species 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- -1 aminoglycoside Chemical compound 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229960000895 doripenem Drugs 0.000 claims 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940118764 francisella tularensis Drugs 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 229960005266 polymyxin b Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960004659 ticarcillin Drugs 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023181425A JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597577P | 2017-12-12 | 2017-12-12 | |
| US62/597,577 | 2017-12-12 | ||
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US62/721,969 | 2018-08-23 | ||
| PCT/US2018/065265 WO2019118632A1 (en) | 2017-12-12 | 2018-12-12 | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181425A Division JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506769A JP2021506769A (ja) | 2021-02-22 |
| JP2021506769A5 true JP2021506769A5 (https=) | 2022-01-06 |
Family
ID=66819724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Pending JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
| JP2023181425A Active JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181425A Active JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12121568B2 (https=) |
| EP (1) | EP3723789A4 (https=) |
| JP (2) | JP2021506769A (https=) |
| KR (1) | KR20200098615A (https=) |
| CN (1) | CN111971058A (https=) |
| AU (1) | AU2018384790C1 (https=) |
| BR (1) | BR112020011433A2 (https=) |
| CA (1) | CA3085644A1 (https=) |
| IL (2) | IL303122A (https=) |
| MX (1) | MX2020006098A (https=) |
| WO (1) | WO2019118632A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
| WO2019126670A1 (en) * | 2017-12-22 | 2019-06-27 | The Rockefeller University | Recombinant pseudomonas aeruginosa lysins |
| CN112368376A (zh) | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
| US10988520B2 (en) * | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| WO2020046747A1 (en) * | 2018-08-23 | 2020-03-05 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3946609A4 (en) * | 2019-04-05 | 2023-05-03 | Contrafect Corporation | LYSINE AND ITS DERIVATIVES WITH BACTERICIDAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA IN THE PRESENCE OF HUMAN SERUM |
| KR102225240B1 (ko) * | 2019-07-03 | 2021-03-10 | 경북대학교 산학협력단 | 다제내성 병원성 세균을 효과적으로 사멸시키는 재조합 항균 단백질 Ablysin의 용도 |
| US20220411473A1 (en) * | 2019-11-14 | 2022-12-29 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| WO2023034646A2 (en) * | 2021-09-03 | 2023-03-09 | Aanika Biosciences, Inc. | Lysecd7 variants and methods of using the same |
| CN114410670B (zh) * | 2022-01-29 | 2024-01-23 | 福建医科大学附属口腔医院 | 一种溶菌酶及其在口腔护理用品中的应用 |
| CN117660413B (zh) * | 2023-12-15 | 2024-06-07 | 华南理工大学 | 一种内溶素Lys009及其工程改造和应用 |
| CN120173923A (zh) * | 2025-05-08 | 2025-06-20 | 浙江大学 | 与PeiR裂解酶高维特征同源的产甲烷菌裂解酶及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| JP5701777B2 (ja) | 2009-02-06 | 2015-04-15 | テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| CA2780079A1 (en) | 2009-11-18 | 2011-05-26 | Basf Plant Science Company Gmbh | Process for the production of fine chemicals |
| EA037276B1 (ru) | 2010-04-27 | 2021-03-03 | Лисандо Аг | Способы устранения или уменьшения бактериальной биопленки |
| GB201018518D0 (en) | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| CA2833409A1 (en) | 2011-04-21 | 2012-10-26 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
| WO2015070912A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
| AU2015279705B2 (en) | 2014-06-26 | 2021-04-01 | The Rockefeller University | Acinetobacter lysins |
| AU2016324307B2 (en) * | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
| CN108103050A (zh) | 2018-02-11 | 2018-06-01 | 中国医药集团总公司四川抗菌素工业研究所 | 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用 |
| CN112368376A (zh) | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
| WO2020046747A1 (en) | 2018-08-23 | 2020-03-05 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
-
2018
- 2018-12-12 BR BR112020011433-2A patent/BR112020011433A2/pt not_active Application Discontinuation
- 2018-12-12 EP EP18889220.2A patent/EP3723789A4/en not_active Withdrawn
- 2018-12-12 AU AU2018384790A patent/AU2018384790C1/en active Active
- 2018-12-12 JP JP2020531748A patent/JP2021506769A/ja active Pending
- 2018-12-12 WO PCT/US2018/065265 patent/WO2019118632A1/en not_active Ceased
- 2018-12-12 CN CN201880089186.9A patent/CN111971058A/zh active Pending
- 2018-12-12 MX MX2020006098A patent/MX2020006098A/es unknown
- 2018-12-12 US US16/772,001 patent/US12121568B2/en active Active
- 2018-12-12 KR KR1020207020090A patent/KR20200098615A/ko not_active Ceased
- 2018-12-12 CA CA3085644A patent/CA3085644A1/en active Pending
- 2018-12-12 IL IL303122A patent/IL303122A/en unknown
- 2018-12-12 IL IL275060A patent/IL275060B2/en unknown
-
2023
- 2023-10-20 JP JP2023181425A patent/JP7646237B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506769A5 (https=) | ||
| JP2021519083A5 (https=) | ||
| IL277119B2 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| JP2024010053A5 (https=) | ||
| RU2018107245A (ru) | Полипептиды лизина, активные против грамотрицательных бактерий | |
| Łusiak-Szelachowska et al. | Bacteriophages and lysins in biofilm control | |
| Łusiak-Szelachowska et al. | Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far | |
| Cobb et al. | Therapeutics and delivery vehicles for local treatment of osteomyelitis | |
| JP2021533728A5 (https=) | ||
| Shahrour et al. | AMPs as anti-biofilm agents for human therapy and prophylaxis | |
| IL313959A (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| Simoes et al. | Novel antibacterial agents: an emergent need to win the battle against infections | |
| MX2020006098A (es) | Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. | |
| JP2021519311A5 (https=) | ||
| CN112218659A (zh) | 用于治疗葡萄球菌感染的治疗性噬菌体组合物 | |
| Zhang et al. | In Vitro Study of Bacteriophage AB3 Endolysin LysAB3 Activity Against Acinetobacter baumannii Biofilm and Biofilm-Bound A. baumannii. | |
| RU2020128276A (ru) | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| Kozlovska et al. | The effect of antimicrobial agents on planktonic and biofilm forms of bacteria that are isolated from chronic anal fissures | |
| Ming et al. | The antibacterial effects of antimicrobial peptides OP-145 against clinically isolated multi-resistant strains | |
| JP2021508501A (ja) | Ｐｓｅｕｄｏｍｏｎａｓ感染症を処置するためのバクテリオファージ組成物 | |
| Borysowski et al. | Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives | |
| JP2022526978A5 (https=) | ||
| JP2023502940A5 (https=) | ||
| BR112021019430A2 (pt) | Lisinas e seus derivados com atividade bactericida contra pseudomonas aeruginosa, na presença de soro humano | |
| RU2020131450A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий |